hepaCAM and p-mTOR Closely Correlate in Bladder Transitional Cell Carcinoma and hepaCAM Expression Inhibits Proliferation via an AMPK/mTOR Dependent Pathway in Human Bladder Cancer Cells
Abstract
Purpose:
We explored the correlation between hepaCAM and activated p-mTOR in bladder transitional cell carcinoma. We also determined whether the antiproliferation effect of hepaCAM is associated with the AMPK/mTOR pathway.
Materials and Methods:
We performed quantitative reverse transcriptase-polymerase chain reaction to determine hepaCAM mRNA expression as well as Western blot to measure hepaCAM and p-mTOR protein levels in 25 men and 5 women. Disease was Ta-T1 in 7 patients, T2-T4 in 23, grade 1 in 13, grade 2 in 9, grade 3 in 8, primary in 13 and recurrent in 17. The WST-8 assay was used to study the effect of hepaCAM on cellular proliferation. p-AMPK, p-mTOR, total AMPK, total mTOR, c-Myc and cyclin D1 were also determined by Western blot.
Results:
hepaCAM mRNA and protein levels were significantly decreased, while p-mTOR protein was remarkably increased in bladder transitional cell carcinoma compared to adjacent tissues (each p <0.01). Spearman correlation analysis revealed that the hepaCAM decrease was associated with an increase in p-mTOR (r = –0.533, p = 0.002). Also, hepaCAM inhibited the proliferation of human bladder transitional cell carcinoma cells. hepaCAM over expression activated AMPK and down-regulated p-mTOR, and its targets c-Myc and cyclin D1. Treatment with the AMPK inhibitor compound C prevented the antiproliferation effect of hepaCAM. Compound C completely blocked hepaCAM induced activation of AMPK and down-regulation of p-mTOR and its targets c-Myc and cyclin D1.
Conclusions:
Results suggest an important correlation between hepaCAM and p-mTOR. hepaCAM can inhibit bladder cancer cell proliferation through an AMPK/mTOR dependent pathway.
References
- 1 : Cancer statistics, 2013. CA Cancer J Clin2013; 63: 11. Google Scholar
- 2 : Global cancer statistics. CA Cancer J Clin2011; 61: 69. Google Scholar
- 3 : Hallmarks of cancer: the next generation. Cell2011; 144: 646. Google Scholar
- 4 : Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol2009; 4: 251. Google Scholar
- 5 : Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J Hepatol2005; 42: 833. Google Scholar
- 6 : Functional significance of the hepaCAM gene in bladder cancer. BMC Cancer2010; 10: 83. Google Scholar
- 7 : Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis2008; 29: 2298. Google Scholar
- 8 : Exon 2 methylation inhibits hepaCAM expression in transitional cell carcinoma of the bladder. Urol Int2010; 85: 347. Google Scholar
- 9 : Exploration of the correlations between interferon-gamma in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-gamma mechanism inhibiting BIU-87 proliferation. J Urol2012; 188: 1346. Link, Google Scholar
- 10 : HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem2011; 112: 2910. Google Scholar
- 11 : The mTOR signalling pathway in human cancer. Int J Mol Sci2012; 13: 1886. Google Scholar
- 12 : Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int2009; 104: 1009. Google Scholar
- 13 : Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene2007; 26: 3291. Google Scholar
- 14 : Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature2006; 441: 424. Google Scholar
- 15 : Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY)2011; 3: 192. Google Scholar
- 16 : AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol2012; 52: 381. Google Scholar
- 17 : Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem Biophys Res Commun2012; 419: 741. Google Scholar
- 18 : Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol2010; 24: 1441. Google Scholar
- 19 : Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog2012; 51: 257. Google Scholar
- 20 : Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol Chem2005; 280: 27366. Google Scholar
- 21 : RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS One2012; 7: e48548. Google Scholar
- 22 : Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology2013; 84: 43. Google Scholar
- 23 : mTOR signaling in disease. Curr Opin Cell Biol2011; 23: 744. Google Scholar
- 24 : The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One2011; 6: e20899. Google Scholar
- 25 : Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology2011; 58: 1054. Google Scholar
- 26 : Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol2010; 17: 2486. Google Scholar
- 27 : A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells2003; 8: 65. Google Scholar
- 28 : The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int2011; 108: E84. Google Scholar
- 29 : Targeting the mTOR signaling network for cancer therapy. J Clin Oncol2009; 27: 2278. Google Scholar
- 30 : mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer2006; 94: 195. Google Scholar
